UVA LVG Seed Fund
Profile and portfolio
UVA LVG Seed Fund is the corporate venture arm of University of Virginia, an education company. It was founded in 2016 and is based in Charlottesville, United States. It invests at the seed stage. Sectors it names: medical devices, biotech and life sciences, cybersecurity, healthcare and digital health.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Seed |
| Sectors | Medical devices, Biotech and life sciences, Cybersecurity, Healthcare and digital health |
| Geography | North America |
| Offices | Charlottesville, United States |
Sources: S1 UVA Licensing & Ventures Group: LVG Seed Fund (funds I and II, team, committee); S3 UVA Licensing & Ventures Group: LVG Seed Fund process (address, board seat, co-investors).
Where it invests and who leads it
Geography
- Headquarters
- Charlottesville, United States
- Offices
- Charlottesville, United States
Investment regionsS1S3
LeadersS4S5
- Robert CreedenManaging Director, UVA LVG Seed Fund & New VenturesFind on LinkedInFirm page
- Matthew RannalsPrincipal, UVA Licensing & Ventures GroupFind on LinkedInFirm page
Key facts
For founders
| Item | What the firm says | Source |
|---|---|---|
| Stages | Seed | S1 |
| Beyond capital | Board seat, help seeking external co-investment, talent and mentor connections through the UVA LVG network | S3 |
| Pitch page | lvg.virginia.edu/funding/uva-lvg-seed-fund | S1 |
Fund vehicles
Portfolio
The firm's portfolio page lists 16 companies.S2
Every company on the UVA LVG Seed Fund list
16 companies, as listed on the firm's own website: 12 listed, 4 exited.S2 Read the firm's list.
Listed 12
- Angara
- BrightSpec
- Ceres Nanosciences
- CytoRecovery
- Direct Spinal Therapeutics
- Merand Pharmaceuticals
- Nanochon
- Navion
- Slate Bio
- TearSolutions
- Vasarya Therapeutics
- WarmHealth Technology
Exited 4
- 510Kardiac Devices
- Astraea
- Mission Secure
- TypeZero Technologies
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
History
Official pages
Read the firm's own pages for current information.
Sources
- S1UVA Licensing & Ventures Group: LVG Seed Fund (funds I and II, team, committee)Firm
- S2UVA Licensing & Ventures Group: LVG Seed Fund portfolioFirm
- S3UVA Licensing & Ventures Group: LVG Seed Fund process (address, board seat, co-investors)Firm
- S4UVA Licensing & Ventures Group: Robert Creeden profileFirm
- S5UVA Licensing & Ventures Group: Matthew Rannals profileFirm
- S6UVA Today: Sound investments, improving lives continue to drive LVG seed fund strategyParent company
- S7UVA Licensing & Ventures Group: TypeZero Technologies (acquired by DexCom in 2018)Firm
- S8UVA Licensing & Ventures Group: 510Kardiac Devices (acquired by Keystone Heart)Firm
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by UVA LVG Seed Fund or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.